Innovative Gastro-Retentive Drug Delivery Technologies for Improving Therapeutic Outcomes of Oral Drugs

Pavan Handa has 25+ years of experience in Business Development, Strategic Planning, Venture Management in the global pharma industry with both drug delivery and specialty pharma. Former SVP for Antares Pharma, senior management roles at various organization including Enzon, Kashiv, Noven, & Union Carbide.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com

Dipen Desai has 15+ years of experience in Complex Product R & D in top companies like Roche, Kashiv & Amneal and key specialization area includes formulation, processes, drug delivery technologies for NCE molecules, 505b2 & complex generics. Was responsible for development of platform technologies like BIOMAXX, GRANDE & KRONOTEC and is an Inventor on 30+ Patents.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com